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Abstract
Background: Terminalia chebula Retz. (Combretaceae) is a traditional herbal medicine that is widely used in the
treatment of diabetes, immunodeficiency diseases, and stomach ulcer in Asia. However, the anti-amnesic effect of T.
chebula has not yet been investigated. The present study was designed to determine whether T. chebula extract (TCE)
alleviates amnesia induced by scopolamine in mice. We also investigated possible mechanisms associated with
cholinergic system and anti-oxidant effects.
Methods: TCE (100 or 200 mg/kg) was orally administered to mice for fourteen days (days 1–14), and scopolamine was
intraperitoneally injected to induce memory impairment for seven days (days 8–14). Learning and memory status were
evaluated using the Morris water maze. Hippocampal levels of acetylcholine (ACh), acetylcholinesterase (AChE) and
choline acetyltransferase (ChAT) were measured ex vivo. Levels of reactive oxygen species (ROS), nitric oxide (NO), and
malondialdehyde (MDA) in the hippocampus were also examined.
Results: In the Morris water maze task, TCE treatment reversed scopolamine-induced learning and memory deficits in
acquisition and retention. TCE reduced hippocampal AChE activities and increased ChAT and ACh levels in the
scopolamine-induced model. Moreover, TCE treatment suppressed scopolamine-induced oxidative damage by
ameliorating the increased levels of ROS, NO, and MDA.
Conclusion: These findings suggest that TCE exerts potent anti-amnesic effects via cholinergic modulation and anti-
oxidant activity, thus providing evidence for its potential as a cognitive enhancer for amnesia.
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Background
As many countries are transforming into aging societies,
an increasing number of individuals in elderly popula-
tions suffers from memory loss and amnesia: worldwide
cost of care and medicine for amnesia was reported to
be $604 billion in 2010 and has been increasing annually
[1]. The prevention or treatment of amnesia is thus an
urgent issue to address.
The hippocampus and cortex are heavily involved in
maintaining and regulating memory; changes in levels of
the neurotransmitter acetylcholine (ACh), which is re-
leased via cholinergic projections to these areas from the
basal forebrain, have been reported to affect cognitive
function and have been implicated in memory loss [2].
Therapeutic interventions aiming to alleviate cognitive
impairments have thus targeted ACh regulation and deg-
radation; acetylcholinesterase (AChE) inhibitors blocking
ACh hydrolysis have been administered to treat amnesia
[3] and are widely prescribed to alleviate general
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cognitive decline [4]. However, these drugs have short
half-lives and adverse reactions, including hepatotoxicity
and nausea [5]. By contrast, medicinal herbs and plants
exhibit fewer side effects and drug interactions [6]; iden-
tifying effective alternative medicines could thus yield
valuable contributions to the treatment of amnesia.
Terminalia chebula Retz. (Combretaceae) has been
used as a traditional medicine to treat diabetes, im-
munodeficiency diseases, and stomach ulcers in across
Asia [7–9]. These medicinal extracts contain terpenes,
flavonoids, and alkaloids, all of which exhibit therapeutic
efficacy [10]. Several in vitro studies have further re-
ported that Terminalia chebula extract (TCE) has anti-
AChE and anti-oxidative effects: TCE has been shown to
inhibit H2O2-induced PC12 cell death [11], and its
methanolic and ethyl acetate fractions have demon stra-
ted varying degrees of AChE inhibitory activity [12, 13].
Despite the progress made to explore the therapeutic
properties of TCE, whether the extract features an anti-
amnesic effect has not yet been investigated.
Scopolamine is a muscarinic ACh receptor antagonist
that can cause learning and memory deficits by disrupt-
ing cholinergic neurotransmission; this compound has
been used to induce amnesia in experimental murine
models [14]. In the present study, we evaluated the
memory-enhancing effects of TCE on scopolamine-
treated mice using the Morris water maze test. We sub-
sequently investigated the levels of ACh, AChE, and
choline acetyltransferase (ChAT) in the hippocampus.
To elucidate any anti-oxidative activities of TCE, we also
ascertained the effects of TCE on reactive oxygen species
(ROS), nitric oxide (NO), and malondialdehyde (MDA)
in mice hippocampal tissue.
Methods
Reagents
Scopolamine hydrobromide, sodium nitrite (NaNO2),
Griess reagent, dimethyl sulfoxide (DMSO), dichloro-
fluorescin diacetate (DCFDA), phosphate buffer, DPPH,
donepezil, and ascorbic acid were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Anti-ChAT and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
were purchased from EMD Millipore (Billerica, MA,
USA). Anti-AChE was obtained from Abcam (Cam-
bridge, MA, USA). Radioimmunoprecipitation assay
(RIPA) buffer was obtained from Thermo Scientific
(Waltham, MA, USA). All horseradish peroxidase-
conjugated secondary antibodies were purchased from
Santa Cruz (Santa Cruz, CA, USA). Chebulic acid, gallic
acid, corilagin, chebulanin, 1,3,6-tri-O-galloyl β-D-
glucose, chebulagic acid, and chebulinic acid were pro-
vided by Professor Sang Hyun Sung (Seoul National
University, College of Pharmacy, South Korea). The pur-
ity of all reference chemical substances was higher than
95%. HPLC-grade water and acetonitrile were purchased
from J.T. Baker (Phillipsburg, NJ, USA).
Plant materials and extraction
Terminalia chebula Retz. is an accepted plant name and
is listed in The Plant List (www.theplantlist.org). The
ripe fruit of Terminalia chebula were purchased from
Kwangmyungdang Medicinal Herbs Co. (Ulsan, South
Korea) and identified by Dr. Go Ya Choi from the K-
herb Research Center (Korea Institute of Oriental Medi-
cine, Daejeon, South Korea). A voucher specimen
(KIOM-Tech5) was deposited at the Convergence Re-
search Center for Diagnosis, Treatment and Care System
of Dementia (Korea Institute of Science and Technology,
Seoul, South Korea).
The ripe fruit of Terminalia chebula (1.0 kg) were
ground and soaked in 70% EtOH (10 L for 15 h) at 40 °
C. The 70% EtOH extracts were filtered, concentrated
(40 °C, EYELA rotary evaporation system, Tokyo Rikaki-
kai, Tokyo, Japan), and dried (PVTFD-100 freeze drier,
Ilshinbiobase, Dongducheon, South Korea) to produce a
powdered extract (268.4 g), which was stored at − 20 °C.
Animals
A total of 56 eight-week-old male C57BL/6 N mice were
obtained from Charles River Co (Gapyeong, South Korea).
We housed four to five animals per cage at a controlled
temperature (23 ± 2 °C) and humidity (50 ± 10%). The
mice were kept on 12 h/12 h light/dark cycle (light from
08:00 A.M.- 08:00 P.M.). The mice received food and
water ad libitum. The institutional animal care and use
committee of Korea Institute of Science and Technology
approved all of the experimental protocols described in
the present study (Permit number: 2016–068). All proce-
dures for the animal study were conducted in accordance
with ARRIVE guidelines, and every effort was made to al-
leviate the suffering of the animals.
Pharmacological treatment
After adaptation for one week, the mice were randomly
divided into six groups: (1) vehicle + vehicle (n = 10); (2)
TCE (200 mg/kg) + vehicle (TCE per se; n = 6); (3) ve-
hicle + scopolamine (scopolamine per se; n = 10); (4)
TCE (100 mg/kg) + scopolamine (n = 10); (5) TCE
(200 mg/kg) + scopolamine (n = 10); and (6) donepezil
(5 mg/kg) + scopolamine (n = 10). The doses of TCE
were determined based on previous report [15]. We used
saline for the vehicle group; TCE was therefore sus-
pended in saline. The mice were orally administered
saline, donepezil, or TCE on days 1–7 to adapt them to
the oral gavage and to adapt their metabolism prior to
behavior tasks; treatment continued on days 8–14. Sco-
polamine (1 mg/kg) was dissolved in saline and treated
intraperitoneally for 7 days (days 8–14). On days 8–14,
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TCE and scopolamine were administered at 60 min and
30 min before training, respectively.
Morris water maze task
Spatial learning and memory was evaluated using the
water maze task as described in a previous study with
minor modifications [16]. All mice underwent behavioral
testing 30 min after scopolamine injection. The water
maze comprised of a white circular tank (183 cm diam-
eter and 58 cm height) with a circular platform (20 cm
diameter). The tank was filled with water (25 ± 1 °C) and
a nontoxic white dye. The platform hidden 0.5 cm be-
neath the water surface in one of tank’s quadrants. The
maze was enveloped in white curtains on which black
patterns were placed as visual cues. All data were moni-
tored using a camera recorder and analyzed using a
video tracking system (HVS Image, Hampton, UK).
On days 8–13, the mice underwent four training trials.
If the mouse found the escape platform within 60 s, the
animal was left on the platform for an additional 20 s. If
the mouse did not find the platform within 60 s, the ani-
mal was placed on the platform and permitted to remain
there for 20 s. The starting positions of the mice were
changed across trials. Search errors were used as a
metric for performance accuracy during training trials:
the distance of the mouse from the platform was sam-
pled 10 times per second, averaged across 1 s, and its
deviation from the most direct search path was calcu-
lated [17]; this method allowed us to remove a time bias
associated with the repositioning of the platform. On
days 11 and 13, all mice were subjected to probe tests
without a platform for a 30 min interval between the last
training trial and the probe trial to examine the reten-
tion of spatial memory. The average swimming speed of
each mouse and their time spent in the target quadrant
was measured.
Sacrifice of mice
On day 14, all mice were sacrificed 30 min after injec-
tion of scopolamine or the vehicle; cervical dislocation
was performed before decapitation to provide each ani-
mal with a quick and painless death. The hippocampus
was placed on ice and stored at − 80 °C until further bio-
chemical analyses. All the mice were handled according
to the animal welfare guidelines issued by Korean Na-
tional Institute of Health. The experimental scheme is
depicted in Fig. 1.
Determination of ex vivo ACh and AChE activity
The activities of hippocampal ACh and AChE were de-
termined using commercially available ACh quantitation
and AChE activity assay kits according to the manufac-
turer’s instructions (Sigma). The absorbance of ACh and
AChE were measured using a microplate reader at
570 nm and 412 nm, respectively (Bio Tek, Winooski,
VT, USA). The values were reported as percentages of
the vehicle control (vehicle + vehicle).
Western blot analysis
Sample preparation and western blotting were per-
formed according to a previous report with minor modi-
fications [16]. The tissues were homogenized in an RIPA
buffer containing protease and phosphatase inhibitors
(GenDEPOT, Barker, TX, USA). They were then centri-
fuged at 14,000 × g for 1 h at 4 °C. The supernatants
were collected, and Bradford assays were performed to
determine protein concentrations. The proteins (30 μg)
were separated using SDS-PAGE and subsequently
transferred to PVDF membranes. After 1 h of incubation
in 5% fat-free dry milk, the membranes were incubated
overnight with primary antibodies against ChAT (1:
1000), AChE (1:1000), and GAPDH (1:5000) at 4 °C. The
bands were normalized to GAPDH and quantified using
an Image Gauge program (Fujifilm, Tokyo, Japan).
Determination of ROS and NO levels
ROS levels were determined according to a previous re-
port [18]. Hippocampal homogenates were incubated
with 15 μl of 1 mM DCFDA in the dark at 37 °C for 1 h.
The fluorescence intensity was measured using a fluores-
cence microplate reader (Spectramax M5, Molecular De-
vices, Pennsylvania, USA) with an excitation and
emission of 488 and 520 nm, respectively. The values
Fig. 1 Schematic description of the experimental design. After a 1-week adaptation, C57BL/6 N mice were orally treated with vehicle (saline), TCE (100 or
200 mg/kg), or donepezil (5 mg/kg) for 14 days. From day 8, the mice were also treated intraperitoneally with vehicle (saline) or scopolamine (1 mg/kg)
for 7 days. The Morris water maze was conducted on days 8–13 to evaluate memory function. All mice were sacrificed on day 14. The hippocampus was
then collected for further biochemical analyses. P.O.; per os (by mouth, orally), I.P.; intraperitoneal
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were reported as a percentage of the vehicle control (ve-
hicle + vehicle).
NO production in the hippocampus was measured using
the Griess method [19]. We incubated 40 μl of the sample
with 160 μl of the Griess reagent in the dark at room
temperature for 15 min. NaNO2 was used to generate a
standard nitrite concentration curve. The purple Azo dye
product was detected at a wavelength of 540 nm. The
amount of NO was expressed as μmole per mg protein.
Estimation of lipid peroxidation
MDA has been widely used to assess lipid peroxidation.
The MDA concentration in the hippocampus was esti-
mated using a commercial lipid peroxidation (MDA)
assay kit according to the manufacturer’s instructions
(Abcam). Its absorbance was measured using a micro-
plate reader at 532 nm. The concentration of MDA was
calculated using a reference standard. The results were
expressed as nmole per mg protein.
High-performance liquid chromatography (HPLC) analyses
HPLC analysis was performed using a Thermo Scientific
Dionex Ultimate 3000 system. TCE and a mixed standard
solution were separated using an YMC Triart C18 column
(4.6 mm× 250 mm, 5.0 μm); the temperature of the col-
umn was maintained at 30 °C during the process. The mo-
bile phases comprised of 0.1% (v/v) formic acid in water
(solvent A) and acetonitrile (solvent B). The following gra-
dient system was used: (B) = 3%–30% (0–30 min) and 30–
90% (30–35 min). System re-equilibration lasted 10 min.
Analysis was performed at a flow rate of 1.0 mL/min with
UV detection at 280 nm. The injection volume was 2 μl.
All analyses were made in triplicate.
Statistical analysis
All data were expressed as the means ± standard error of
the mean (S.E.M). Statistical analysis was performed using
SPSS software (SPSS Inc., Chicago, IL, USA). The search
error data from the behavioral test were analyzed using
two-way repeated analysis of variance (ANOVA). The cor-
relation between obtained data was analyzed by the Pear-
son test. Other data were analyzed using one-way
ANOVA. Post hoc analyses were subsequently performed
using the least significant difference (LSD) test for com-
parison among experimental groups. The statistical signifi-
cance was defined as p values of less than 0.05.
Results
Effect of TCE on learning and memory improvement in
the Morris water maze
All experimental groups showed no toxicity in terms of
general behavioral changes or mortality, and no adverse
events were observed. Mouse body weights were mea-
sured on days 1 through 14 during treatment with TCE,
donepezil, and scopolamine; no significant differences
were found among the different groups (data not shown).
The Morris water maze test was performed to determine
whether TCE attenuates learning and memory impairment
induced by scopolamine. Two-way repeated ANOVA for
search error revealed significant between-group treatment
effects (F(5,50) = 15.468, p < 0.001), training effects (F(5,250) =
78.640, p < 0.001), and treatment × training interaction ef-
fects (F(25250) = 3.310, p < 0.001). As shown in Fig. 2a,
scopolamine per se treatment showed a higher search error
than VEH+VEH control during the 6 days of training; this
result suggests that scopolamine triggered learning deficits
(p < 0.001). However, the scopolamine-treated mice that re-
ceived either 100 or 200 mg/kg of TCE performed signifi-
cantly better than those that received scopolamine alone,
indicating that learning impairment was attenuated follow-
ing TCE treatment (p < 0.05 and p < 0.001, respectively).
Mice treated with donepezil (5 mg/kg), a well-known revers-
ible AChE inhibitor used as a positive control, showed better
performance than mice injected with scopolamine alone (p
< 0.001). There was no difference in TCE per se-treated
mice compared to vehicle-treated mice. In addition, the
swimming speed did not differ among the groups,
indicating that the locomotor activity of mice was not
affected by scopolamine, TCE, or donepezil (Fig. 2b, F(5,50)
= 0.766, p = 0.578). We also measured the body weights of
all mice during drug treatment and behavioral tasks, but
there was no significant difference among the six groups
(data not shown).
The mice underwent two probe trials to determine
memory retention on days 11 (1st probe) and 13 (2nd
probe). In the 1st probe test, one-way ANOVA re-
vealed significant differences between-group effects
(F(5,50) = 9.568, p < 0.001). Post hoc analyses showed
that the time to the target quadrant of the scopolam-
ine per se-treated group was significantly lower than
that of the vehicle control (Fig. 2c; p < 0.001). Treat-
ment with TCE (200 mg/kg), however, significantly in-
creased the time to the target quadrant (p < 0.05).
Donepezil showed effects similar to those of TCE
(200 mg/kg) treatment (p < 0.05). In addition, there
was no difference between the TCE per se-treated
mice and the vehicle control.
In the 2nd probe test, one-way ANOVA revealed
significant between-group effects (F(5,50) = 5.411, p < 0.001).
Similar to the results from the 1st probe, there was a
significant difference between the VEH+VEH and VEH+
SCO groups (p < 0.001). Though TCE-treated mice spent
more time in the target quadrant than scopolamine
per se group, the effect was nonsignificant. The swim-
ming routes further confirmed that TCE-treated mice
remained in the target quadrant longer than did the
scopolamine per se treated mice (Fig. 2d). Taken
together, these results suggest that TCE ameliorated
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induced cognitive impairments related to spatial
learning and memory.
Effect of TCE on cholinergic system in the hippocampus
To investigate whether TCE administration had an ef-
fect on cholinergic pathways, ACh levels in the
hippocampus was measured. One-way ANOVA indi-
cated significant between-group effects (F(5,17) = 4.626,
p = 0.014). As shown in Fig. 3a, scopolamine per se-
treated mice significantly reduced hippocampal ACh
levels in the hippocampus relative to vehicle controls
(p < 0.01). Treatment with TCE (200 mg/kg) induced
a significant increase in ACh levels when compared
with the VEH + SCO group (p < 0.05). Donepezil
showed a significant increase in ACh levels relative to
vehicle controls (p < 0.05); this effect was absent when
vehicle controls were compared with the TCE per se
treated mice compared to vehicle control (Fig. 3a).
We also measured hippocampal AChE activity to elu-
cidate the underlying mechanism of a possible TCE-
induced increase of ACh levels. One-way ANOVA indi-
cated a statistically significant between-group effects
(F(5,29) = 10.999, p < 0.001). In the scopolamine-injected
group, a significant increase in AChE activity was ob-
served in the hippocampus (Fig. 3b; p < 0.001). TCE
administration inhibited AChE activation induced by
scopolamine treatment in a dose-dependent manner
(Fig. 3b; p < 0.01 for 100 mg/kg and p < 0.001 for
200 mg/kg). Donepezil also resulted in significant inhib-
ition of AChE activity (p < 0.001). The difference in
AChE levels between the TCE per se treatment and
vehicle treatment were nonsignificant.
Fig. 2 Effect of TCE on scopolamine- induced memory impairment in the Morris water maze task. a Acquisition of spatial memory in mice. The
cumulative search error (distance from the mice to escape platform) during 6 days of training is shown. The number in parentheses indicates the
size per group (n). b Mean swimming speed of each group on the first day of training. c Retention of spatial memory in mice. Time spent in the
target quadrant during the probe trial on day 11 (1st) and 13 (2nd) is shown. d Representative swimming tracks of mice in each group during
the 1st probe test. The bright part indicates the target quadrant. The data are expressed as the means ± S.E.M. ***p < 0.001 compared with VEH +
VEH; #p < 0.05, ###p < 0.001 compared with VEH + SCO. VEH; vehicle, SCO; scopolamine, DON; donepezil
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To examine whether TCE treatment influenced protein
expression associated with the cholinergic pathway, we
performed western blotting for ChAT and AChE on hip-
pocampal tissue (Fig. 4a). One-way ANOVA revealed
between-group effects (F (5,29) = 5.276, p = 0.002) in ChAT
expression. Consistent with a previous report [16], there
were no significant differences between vehicle control
and scopolamine per se-treated mice (Fig. 4b). Treatment
with scopolamine and TCE at a dose of 200 mg/kg signifi-
cantly up-regulated the expression of ChAT in the
hippocampus (Fig. 4b; p < 0.05). Donepezil also showed
significantly increased ChAT expression (p < 0.01). More-
over, one-way ANOVA indicated between-group changes
in the AChE expression levels in the hippocampus (F (5,29)
= 3.882, p = 0.010): TCE at 200 mg/kg reversed the
scopolamine-mediated increase of AChE (Fig. 4c; p < 0.01)
and Donepezil induced a significant decrease in AChE
expression (p < 0.001). TCE per se treatment did not ex-
hibit any significant changes when compared with vehicle
treatment alone. These findings suggest that TCE may
Fig. 3 Effect of TCE on hippocampal ACh levels and AChE activity in the scopolamine-induced model. a The level of ACh in hippocampal tissue is
shown (n = 3 per group). b Hippocampal AChE levels are presented (n = 5 per group). Bar graph is expressed as a percentage of VEH + VEH control.
The data are expressed as the means ± S.E.M. *p < 0.05, ***p < 0.001 compared with VEH + VEH; #p < 0.05, ##p < 0.01, ###p < 0.001 compared with VEH
+ SCO. VEH; vehicle, SCO; scopolamine, DON; donepezil
Fig. 4 Effect of TCE on hippocampal ChAT and AChE expression in the scopolamine-induced model. a Representative protein bands of ChAT and
AChE. GAPDH was used as a loading control. b The quantification of ChAT expression is shown (n = 5 per group). c The quantification of AChE
expression is shown (n = 5 per group). Bar graph is expressed as a percentage of VEH + VEH control. The data are expressed as the means ± S.E.M.
*p < 0.05 compared with VEH + VEH; #p < 0.05, ##p < 0.01, ###p < 0.001 compared with VEH + SCO. VEH; vehicle, SCO; scopolamine, T; TCE,
DON; donepezil
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protect against scopolamine-induced memory impairment
through mechanisms related to cholinergic function.
Effect of TCE on oxidative damage in the hippocampus
We investigated ROS, NO, and MDA levels in hippocampal
tissue to determine whether TCE inhibits oxidative damage
induced by scopolamine. Regarding the effect of TCE on the
ROS production, one-way ANOVA revealed significant
between-group effects (F(5,17) = 8.592, p < 0.001). The ROS
level was significantly increased in scopolamine-treated mice
relative to vehicle-treated mice (p < 0.001); this elevation was
significantly attenuated after treatment with either TCE at
200 mg/kg or donepezil (Fig. 5a; p < 0.01). One-way
ANOVA revealed significant between-group effects on NO
production (F(5,17) = 10.631, p < 0.001). Scopolamine admin-
istration notably up-regulated NO levels in the hippocampus
(p < 0.001). Administration of TCE at 100 mg/kg induced a
nonsignificant attenuation of NO levels, while the 200 mg/
kg dosage induced a significant mitigation (Fig. 5b; p < 0.01).
Donepezil also resulted in the significant reduction of NO
concentration (p < 0.001). MDA levels in the hippocampus
were also measured to determine the effect of TCE on lipid
peroxidation; One-way ANOVA indicated significant
changes between groups (F(5,17) = 43.445, p < 0.001). Com-
pared with the vehicle treatment group, scopolamine
treatment generated a significant increase in MDA con-
centrations (p < 0.001). TCE treatment (100 and 200 mg/
kg) affected a significant decrease of MDA levels relative
to scopolamine treatment (Fig. 5c; p < 0.05 and p < 0.001,
respectively). A reduced MDA concentration was also
observed in the donepezil treatment group (p < 0.001).
These results suggest that TCE effectively attenuated
oxidative damage induced by scopolamine.
HPLC analysis of TCE
The HPLC chromatogram characteristics of the seven
compounds in TCE (chebulic acid, gallic acid, corilagin,
chebulanin, 1,3,6-tri-O-galloyl β-D-glucose, chebulagic
acid, and chebulinic acid), including the retention time
and UV spectrum, were determined. The retention times
for the seven standards of chebulic acid, gallic acid, cori-
lagin, chebulanin, 1,3,6-tri-O-galloyl β-D-glucose, chebu-
lagic acid, and chebulinic acid were 5.69, 9.60, 20.34, 20.
76, 22.43, 24.75, and 28.04 min, respectively (Fig. 6 and
Table 1). All of the calibration curves for the seven com-
pounds exhibited good linearity (r2 > 0.9990). Table 1
Fig. 5 Effect of TCE on oxidative damage induced by scopolamine in the hippocampus of mice. a DCF fluorescence in the hippocampus was
determined to assess effect of TCE on ROS production (n = 3 per group). Bar graph is expressed as the percentage of VEH + VEH control. b NO
levels in the hippocampus are shown (n = 3 per group). c MDA concentration in the hippocampus is determined to assess the effect of TCE on
lipid peroxidation (n = 3 per group). The data are expressed as the means ± S.E.M. ***p < 0.001 compared with VEH + VEH; #p < 0.05, ##p < 0.01,
###p < 0.001 compared with VEH + SCO. VEH; vehicle, SCO; scopolamine, DON; donepezil
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shows that chebulagic acid (169.7 mg/g) and chebulinic
acid (263.7 mg/g) are the principal components of TCE.
Discussion
Terminalia chebula, the main material examined in the
present study, is widely used as a medicinal herb to treat
diabetes, asthma, sore throat, and other conditions [20].
Much research has already been conducted to investi-
gate its activity and applications; however, the anti-
AChE and anti-oxidative effects of Terminalia chebula
have primarily been observed in vitro. Though one study
previously reported nootropic effects of TCE in normal
mice in vivo [21], whether TCE could alleviate amnesia
following cholinergic blockade remains unknown. The
present study therefore examine the anti-amnesic effect
of TCE using mice treated with scopolamine, an inhibi-
tor of central cholinergic transmission. Based on findings
from previous reports, we administered TCE at 100 and
200 mg/kg doses [15, 21]. As confirmed by the results
the water maze trials, the findings demonstrate that TCE
has an anti-amnesic effect on scopolamine-treated mice.
We also observed the anti-AChE and anti-oxidative ef-
fects of TCE using several assays, including ex vivo ex-
periments. In this respect, Terminalia chebula could
potentially represent an important alternative drug for
addressing amnesia.
In the present study, we confirmed that TCE is com-
posed of seven compounds and ascertained their quanti-
tative differences through an HPLC analysis. Most of the
compounds found in TCE are phenolic, including hydro-
lyzable tannins. We recently reported that chebulic acid
and chebulanin showed AChE inhibitory activity at a
concentration of 10 μM. In particular, chebulanin
showed the most potent AChE inhibitory activity, with
an IC50 of 21.36 μM [22]. Considering the anti-oxidative
effects of both compounds as reported in previous stud-
ies [23, 24], chebulanin and chebulic acid may be the
major anti-amnesic constituents of TCE. Future in vivo
studies are required to determine the utility of these
compounds in developing pharmacological agents.
ACh signaling plays a crucial role in maintaining
memory function [25]. Since patients with memory dis-
orders typically exhibit cholinergic deficits (i.e., abnor-
mally elevated AChE activity and reduced ACh levels),
many studies have focused on the restoration of the
cholinergic systems to improve memory [26]. Accord-
ing to a previous report, scopolamine causes memory
impairments by means of affecting cholinergic
Fig. 6 Representative HPLC-UV chromatogram. a HPLC-UV chromatogram of TCE. b HPLC-UV chromatogram of seven standard compounds in
the mixed solution. c Chemical structures of the seven main compounds in TCE
Table 1 Proportion of the seven TCE constituent compounds a
No. Analytes Content (%)
1 Chebulic acid 1.60
2 Gallic acid 2.85
3 Corilagin 2.76
4 Chebulanin 2.56
5 1,3,6-Tri-O-galloyl β-D-glucose 2.82
6 Chebulagic acid 16.97
7 Chebulinic acid 26.37
aAll analyses were conducted in triplicate
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pathways [27]; the scopolamine model used in the
present study is therefore suitable for assessing the ef-
fectiveness of anti-amnesic agents.
In the present investigation, all mice underwent analysis
using the Morris water maze to evaluate learning and
memory function. The water maze serves as a powerful
and sensitive tool for assessing hippocampal-dependent
spatial learning and memory [28]. We conducted a cumu-
lative search error indicating the distance of each mouse
from the platform during daily training sessions to
characterize spatial learning,; the values thus reflect both
proximity and latency [17]. The results demonstrated that
TCE treatment improved search error during training tri-
als, suggesting the amelioration of learning impairment.
Moreover, the probe test revealed that TCE administration
at a dose of 200 mg/kg elevated the time spent in the tar-
get quadrant; the results thus evince the efficacy of TCE
in improving memory retention. Further study is needed
to investigate whether TCE might affect the retrieval of
memory, another stage of the memory process.
Our biochemical analyses further demonstrated that
TCE exhibits therapeutic effects on cholinergic dys-
function in the hippocampus: a major region of the
brain involved in learning and memory function, par-
ticularly in spatial memory [29]. Many pathological
changes to brain structure and function have been de-
tected in the hippocampus of patients with amnesia;
specifically, abnormalities in the cholinergic system
were observed in the hippocampus of amnesia pa-
tients [26]. It has also been reported that the hippo-
campus is vulnerable to damage after scopolamine
administration [30]. In this context, TCE administra-
tion mitigated AChE activity and expression in hippo-
campal tissue. We also found a negative correlation
between AChE activity and the time spent in the tar-
get quadrant (Additional file 1: Figure S1). Although
ChAT expression was not affected by scopolamine ad-
ministration, increased ChAT expression was observed
in the scopolamine + TCE (200 mg/kg) group. We
did not, however, observe significant differences in
hippocampal ChAT expression between the vehicle
control and TCE per se-treated mice. Further studies
are required to reveal the cause of these differences
or lack thereof. Taken together, these results suggest
that the regulation of the cholinergic system may
underlie the anti-amnesic effects of TCE.
Increase in oxidative stress with age is the main risk
factor for amnesia; the excessive generation of oxidative
products, including ROS, contributes to the disturbance
of calcium homeostasis, increased neurotoxic activity,
and subsequent elevated lipid peroxidation [31]. Delay-
ing or preventing oxidative damage using anti-oxidants
may therefore present a promising therapeutic strategy
for treating amnesia. We investigated the anti-oxidative
effects of TCE using an in vivo scopolamine model as
this model encompasses notable oxidative damage. In
our study, increased ROS and MDA concentrations were
correlated with memory impairment (Additional file 1:
Figure S1). The results showed that TCE treatment at-
tenuated up-regulated levels of ROS, NO, and MDA in-
duced by scopolamine in the hippocampal region, which
is vulnerable to oxidative stress [32]. TCE treatment may
thus alleviate amnesic symptoms by exerting anti-
oxidative effects.
A previous study has reported that levels of AChE
splice variants were increased under conditions of
oxidative-stress [33]. We therefore analyzed the cor-
relation between AChE activity and oxidative markers
and observed a significant correlation between AChE
activity and ROS, as well as between AChE activity
and MDA (Additional file 2: Figure S2); our findings
agree with those of a previous study [34]. These re-
sults therefore suggest a possible interaction between
scopolamine-induced cholinergic modulation and oxi-
dative stress. However, further research is needed to
clarify the mechanism underlying the interaction.
Our study has several limitations. First, we re-
stricted our investigation to spatial learning and
memory. The effect of TCE on other types of learning
and memory (e.g., object recognition memory and
fear memory) remains unknown. Second, we did not
investigate which channel(s) or receptor(s) are in-
volved in cholinergic transmission after the adminis-
tration of TCE. Lastly, we do not know whether TCE
has a beneficial effect on amnesia in chronic neurode-
generative diseases, such as Alzheimer’s disease (AD).
Further studies are therefore necessary to explore the
anti-amnesic effects of TCE using a transgenic animal
model of AD.
Conclusion
The present study was conducted to evaluate the anti-
amnesic activity of TCE in a scopolamine-induced
murine model of memory impairment. Our data demon-
strated that TCE administration ameliorated cognitive
deficits measured by performance in water maze tasks.
TCE treatment reduced AChE and increased ChAT
expression, thus elevating ACh levels in hippocampal tis-
sue of scopolamine-induced mice. Furthermore, de-
creases ROS, NO, and MDA levels in the hippocampus
evince the anti-oxidative capability of TCE treatment.
The results indicate that the underlying mechanism of
learning and memory improvement may involve modu-
lations of the cholinergic system and the reduction of
oxidative stress. These findings thus provide evidence
for the potential of TCE extract as a natural, alternative
treatment for amnesia.
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Additional files
Additional file 1: Figure S1. Correlation graph between behavior test
and measured biomarkers. (A) Correlation of time in target quadrant of the
first probe test (%) with AChE activity (% of VEH + VEH). (B) Correlation of
time in target quadrant of the first probe test (%) with DCF fluorescence (%
of VEH + VEH). (C) Correlation of time in target quadrant of the first probe
test (%) with MDA concentration (nM/mg protein). (TIF 1767 kb)
Additional file 2: Figure S2. Correlation graph between AChE activity
and oxidative markers. (A) Correlation of AChE activity (% of VEH + VEH)
with DCF fluorescence (% of VEH + VEH). (B) Correlation of AChE activity
(% of VEH + VEH) with MDA concentration (nM/mg protein). (TIF 1099 kb)
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